Future of the drug label: perspectives from a multi stakeholder dialogue

C.C. Gispen-de Wied; J. Weemers; W. Boon; P.G.M. Mol; P. Stolk

doi:10.1111/bcp.14070

Future of the drug label: perspectives from a multi stakeholder dialogue

C.C. Gispen-de Wied
, J. Weemers
, W. Boon
, P.G.M. Mol
, P. Stolk

Medicines Evaluation Board

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

'Regulating drugs does not end when market access has been granted. Monitoring drugs over the life-cycle has become state of the art, inherent to evolving legislation and societal need. Here, we explore how the drug label could move along in a changing playing-field, and become a sustainable label for the future. A dialogue between academia, government, the pharmaceutical industry, and patient/societal organizations was organized by the Regulatory Science Network Netherlands, RSNN. This is their view.'

Original language	English
Pages (from-to)	2442-2445
Number of pages	4
Journal	British Journal of Clinical Pharmacology
Volume	85
Issue number	10
Early online date	2019
DOIs	https://doi.org/10.1111/bcp.14070
Publication status	Published - 18 Jul 2019

Keywords

label
regulatory authorities
SmPC
adult
article
drug industry
government
human
Netherlands
organization

Access to Document

10.1111/bcp.14070

future of the drug labelFinal published version, 503 KB

Cite this

@article{945bce3973e54e3dbbe51810d5074a42,

title = "Future of the drug label: perspectives from a multi stakeholder dialogue",

abstract = "'Regulating drugs does not end when market access has been granted. Monitoring drugs over the life-cycle has become state of the art, inherent to evolving legislation and societal need. Here, we explore how the drug label could move along in a changing playing-field, and become a sustainable label for the future. A dialogue between academia, government, the pharmaceutical industry, and patient/societal organizations was organized by the Regulatory Science Network Netherlands, RSNN. This is their view.'",

keywords = "label, regulatory authorities, SmPC, adult, article, drug industry, government, human, Netherlands, organization",

author = "\{Gispen-de Wied\}, C.C. and J. Weemers and W. Boon and P.G.M. Mol and P. Stolk",

year = "2019",

month = jul,

day = "18",

doi = "10.1111/bcp.14070",

language = "English",

volume = "85",

pages = "2442--2445",

journal = "British Journal of Clinical Pharmacology",

issn = "0306-5251",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "10",

}

TY - JOUR

T1 - Future of the drug label

T2 - perspectives from a multi stakeholder dialogue

AU - Gispen-de Wied, C.C.

AU - Weemers, J.

AU - Boon, W.

AU - Mol, P.G.M.

AU - Stolk, P.

PY - 2019/7/18

Y1 - 2019/7/18

N2 - 'Regulating drugs does not end when market access has been granted. Monitoring drugs over the life-cycle has become state of the art, inherent to evolving legislation and societal need. Here, we explore how the drug label could move along in a changing playing-field, and become a sustainable label for the future. A dialogue between academia, government, the pharmaceutical industry, and patient/societal organizations was organized by the Regulatory Science Network Netherlands, RSNN. This is their view.'

AB - 'Regulating drugs does not end when market access has been granted. Monitoring drugs over the life-cycle has become state of the art, inherent to evolving legislation and societal need. Here, we explore how the drug label could move along in a changing playing-field, and become a sustainable label for the future. A dialogue between academia, government, the pharmaceutical industry, and patient/societal organizations was organized by the Regulatory Science Network Netherlands, RSNN. This is their view.'

KW - label

KW - regulatory authorities

KW - SmPC

KW - adult

KW - article

KW - drug industry

KW - government

KW - human

KW - Netherlands

KW - organization

U2 - 10.1111/bcp.14070

DO - 10.1111/bcp.14070

M3 - Article

SN - 0306-5251

VL - 85

SP - 2442

EP - 2445

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

IS - 10

ER -

Future of the drug label: perspectives from a multi stakeholder dialogue

Abstract

Keywords

Access to Document

Fingerprint

Cite this